ZIM Laboratories Limited

ZIMLAB

INE518E01015

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:55 08/07/2024 BST			5-day change	1st Jan Change
109.2 ^INR	0.00%		+1.16%	-5.29%

07-02	ZIM Laboratories Invests INR6.8 Million in Subsidiary ZIMTAS	MT
05-14	Zim Laboratories' Consolidated Profit Climbs in Fiscal Q4; Shares Slide 5%	MT

SIA ZIM Laboratories Limited announced that it expects to receive INR 4 million in funding from ZIM Laboratories Limited

May 12, 2024

SIA ZIM Laboratories Limited announced that it will receive up to INR 4,000,000 in an equity round of funding from returning investor ZIM Laboratories Limited on May 13, 2024. The transaction was approved by the board of directors of the company.

Latest news about ZIM Laboratories Limited

ZIM Laboratories Invests INR6.8 Million in Subsidiary ZIMTAS	07-02	MT
Zim Laboratories' Consolidated Profit Climbs in Fiscal Q4; Shares Slide 5%	05-14	MT
ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-13	CI
ZIM Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-13	CI
Zimtas Pty Ltd announced that it expects to receive INR 20 million in funding from ZIM Laboratories Limited	05-12	CI
SIA ZIM Laboratories Limited announced that it expects to receive INR 4 million in funding from ZIM Laboratories Limited	05-12	CI
ZIM Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-29	CI
ZIM Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-01	CI
Zim Laboratories Arm Gets License to Operate Business in Dubai, UAE	16/10/23	MT
ZIM Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
ZIM Laboratories Limited agreed to acquire 99% stake in Zimtas Pty Ltd for approximately AUD 0.01 million.	27/06/23	CI
CARE Gives BBB Rating to Zim Laboratories' Long-term Bank Financing; Outlook Stable	07/06/23	MT
ZIM Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	19/05/23	CI
ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	19/05/23	CI
ZIM Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	03/02/23	CI
ZIM Laboratories Issues Over 32 Million Bonus Shares	23/12/22	MT
ZIM Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	12/11/22	CI
Acuite Retains BBB- Rating on Zim Laboratories' Bank Loans; Raises Outlook to Positive	31/08/22	MT
ZIM Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	26/07/22	CI
ZIM Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	21/05/22	CI
ZIM Laboratories Limited Announces Grant of Marketing Authorization for Sildenafil Citrate 50 mg Orally Dissolving Film in Spain, Europe	12/05/22	CI
ZIM Laboratories Limited Announces Board Changes, Effective April 1, 2022	31/03/22	CI
ZIM Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	30/10/21	CI
ZIM Laboratories : Acuite Ratings & Research Upgrades Zim Laboratories' Rating to BBB-; Keeps Stable Outlook	23/09/21	MT
ZIM Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	13/08/21	CI

Chart ZIM Laboratories Limited

Duration

Period

More charts

Company Profile

ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.

Sector

Pharmaceuticals

Calendar

05/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZIM LABORATORIES LIMITED	-5.29%	64.95M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+23.58%	45.07B
OTSUKA HOLDINGS CO., LTD.	+30.84%	23.39B
SANDOZ GROUP AG	+25.28%	16.08B
CIPLA LIMITED	+19.32%	14.6B
ZYDUS LIFESCIENCES LIMITED	+67.99%	14.01B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-13.00%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.36%	5.64B